| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| MicroRNAs | 9 | 2023 | 685 | 2.510 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2023 | 102 | 2.490 |
Why?
|
| Kidney Neoplasms | 4 | 2023 | 159 | 2.380 |
Why?
|
| Lung Neoplasms | 13 | 2024 | 668 | 2.330 |
Why?
|
| Urinary Bladder Neoplasms | 14 | 2023 | 105 | 2.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2024 | 166 | 1.120 |
Why?
|
| Early Detection of Cancer | 10 | 2024 | 319 | 1.040 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2024 | 1615 | 0.880 |
Why?
|
| Adenocarcinoma | 2 | 2024 | 342 | 0.870 |
Why?
|
| Cadherins | 7 | 2008 | 80 | 0.780 |
Why?
|
| Biomarkers, Tumor | 5 | 2020 | 506 | 0.710 |
Why?
|
| Gene Expression Profiling | 7 | 2021 | 771 | 0.700 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2021 | 8 | 0.700 |
Why?
|
| Gene Expression | 1 | 2021 | 839 | 0.580 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2023 | 523 | 0.490 |
Why?
|
| Cell Movement | 6 | 2023 | 451 | 0.470 |
Why?
|
| Urethral Stricture | 3 | 2021 | 69 | 0.460 |
Why?
|
| Neoplasm Staging | 5 | 2024 | 501 | 0.440 |
Why?
|
| Neoplasm Invasiveness | 13 | 2022 | 278 | 0.440 |
Why?
|
| Humans | 44 | 2024 | 63292 | 0.390 |
Why?
|
| DNA, Neoplasm | 3 | 2014 | 57 | 0.380 |
Why?
|
| Lichen Sclerosus et Atrophicus | 3 | 2021 | 20 | 0.380 |
Why?
|
| Middle Aged | 16 | 2024 | 17550 | 0.350 |
Why?
|
| Aged | 14 | 2024 | 14392 | 0.350 |
Why?
|
| Carcinoma, Transitional Cell | 5 | 2009 | 42 | 0.350 |
Why?
|
| Cell Line, Tumor | 10 | 2023 | 1464 | 0.340 |
Why?
|
| Catechin | 2 | 2007 | 34 | 0.330 |
Why?
|
| Male | 23 | 2024 | 29820 | 0.320 |
Why?
|
| Cell Proliferation | 3 | 2023 | 985 | 0.300 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 421 | 0.290 |
Why?
|
| Tea | 2 | 2007 | 32 | 0.290 |
Why?
|
| Nephrectomy | 2 | 2020 | 91 | 0.290 |
Why?
|
| Biopsy | 4 | 2019 | 444 | 0.280 |
Why?
|
| Prognosis | 8 | 2022 | 1747 | 0.280 |
Why?
|
| Anticarcinogenic Agents | 1 | 2007 | 78 | 0.260 |
Why?
|
| Disease Progression | 4 | 2020 | 1164 | 0.260 |
Why?
|
| Risk Assessment | 4 | 2021 | 2076 | 0.260 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2005 | 325 | 0.260 |
Why?
|
| Female | 18 | 2024 | 32790 | 0.250 |
Why?
|
| Kidney | 2 | 2020 | 447 | 0.250 |
Why?
|
| Prostate | 2 | 2018 | 90 | 0.250 |
Why?
|
| Neoplasm Grading | 3 | 2021 | 92 | 0.250 |
Why?
|
| Prostatic Neoplasms | 3 | 2018 | 416 | 0.240 |
Why?
|
| Cohort Studies | 3 | 2021 | 2569 | 0.230 |
Why?
|
| Transfection | 4 | 2021 | 692 | 0.230 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 691 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 345 | 0.210 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2003 | 7 | 0.210 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2023 | 18 | 0.210 |
Why?
|
| Hospitalization | 2 | 2021 | 1359 | 0.210 |
Why?
|
| Carcinoma | 1 | 2004 | 122 | 0.210 |
Why?
|
| Urologic Surgical Procedures, Male | 2 | 2021 | 52 | 0.200 |
Why?
|
| Administration, Intravesical | 1 | 2023 | 13 | 0.200 |
Why?
|
| Retrospective Studies | 10 | 2023 | 6631 | 0.200 |
Why?
|
| Signal Transduction | 4 | 2007 | 3034 | 0.200 |
Why?
|
| Survival Analysis | 3 | 2021 | 581 | 0.200 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 125 | 0.200 |
Why?
|
| Urethra | 2 | 2021 | 75 | 0.200 |
Why?
|
| Lung | 3 | 2023 | 946 | 0.190 |
Why?
|
| High Mobility Group Proteins | 3 | 2007 | 24 | 0.190 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2021 | 5 | 0.180 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2023 | 140 | 0.180 |
Why?
|
| Vascular Calcification | 1 | 2021 | 25 | 0.180 |
Why?
|
| Mutation | 3 | 2016 | 2607 | 0.170 |
Why?
|
| Carcinoma, Lobular | 1 | 2001 | 26 | 0.170 |
Why?
|
| Sensitivity and Specificity | 4 | 2017 | 1146 | 0.170 |
Why?
|
| Carcinoma in Situ | 1 | 2001 | 35 | 0.170 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2020 | 297 | 0.170 |
Why?
|
| Pectoralis Muscles | 1 | 2020 | 8 | 0.170 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 1082 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 257 | 0.170 |
Why?
|
| Emphysema | 1 | 2020 | 39 | 0.170 |
Why?
|
| Immunotherapy | 1 | 2023 | 255 | 0.170 |
Why?
|
| Trans-Activators | 2 | 2005 | 313 | 0.170 |
Why?
|
| Breast Neoplasms | 3 | 2007 | 1195 | 0.160 |
Why?
|
| Bariatric Surgery | 1 | 2020 | 60 | 0.160 |
Why?
|
| Repressor Proteins | 3 | 2007 | 347 | 0.160 |
Why?
|
| Cluster Analysis | 2 | 2017 | 263 | 0.160 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 2457 | 0.160 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 5449 | 0.160 |
Why?
|
| Adult | 7 | 2022 | 16785 | 0.150 |
Why?
|
| Obesity, Morbid | 1 | 2020 | 98 | 0.150 |
Why?
|
| Microarray Analysis | 2 | 2017 | 65 | 0.150 |
Why?
|
| Pneumonia | 1 | 2021 | 290 | 0.140 |
Why?
|
| RNA, Small Interfering | 2 | 2023 | 920 | 0.140 |
Why?
|
| Immunohistochemistry | 6 | 2019 | 893 | 0.140 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2010 | 36 | 0.140 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 310 | 0.140 |
Why?
|
| Mice | 6 | 2023 | 10816 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2007 | 217 | 0.130 |
Why?
|
| Blotting, Western | 6 | 2010 | 608 | 0.130 |
Why?
|
| Dasatinib | 1 | 2016 | 5 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2016 | 31 | 0.130 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2016 | 26 | 0.120 |
Why?
|
| src-Family Kinases | 1 | 2016 | 64 | 0.120 |
Why?
|
| Animals | 10 | 2023 | 20622 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 197 | 0.110 |
Why?
|
| Neoplasm Proteins | 2 | 2010 | 281 | 0.110 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2014 | 8 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2010 | 542 | 0.110 |
Why?
|
| Cytoskeletal Proteins | 3 | 2005 | 200 | 0.110 |
Why?
|
| Catenins | 3 | 2007 | 14 | 0.100 |
Why?
|
| Wound Healing | 2 | 2005 | 189 | 0.100 |
Why?
|
| Surgical Flaps | 2 | 2005 | 118 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 695 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2005 | 212 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2014 | 198 | 0.100 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 2003 | 16 | 0.100 |
Why?
|
| Enzyme Inhibitors | 2 | 2005 | 373 | 0.100 |
Why?
|
| Neoplasms | 2 | 2022 | 1361 | 0.100 |
Why?
|
| Skin | 2 | 2005 | 372 | 0.090 |
Why?
|
| Young Adult | 2 | 2022 | 4686 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 385 | 0.090 |
Why?
|
| Neoplasm Transplantation | 2 | 2007 | 165 | 0.080 |
Why?
|
| Genes, Suppressor | 1 | 2010 | 6 | 0.080 |
Why?
|
| STAT3 Transcription Factor | 2 | 2007 | 70 | 0.080 |
Why?
|
| Risk | 2 | 2021 | 377 | 0.080 |
Why?
|
| Cell Adhesion Molecules | 2 | 2007 | 90 | 0.080 |
Why?
|
| Mice, Nude | 2 | 2007 | 273 | 0.080 |
Why?
|
| Transplantation, Heterologous | 2 | 2007 | 229 | 0.080 |
Why?
|
| Tissue Array Analysis | 3 | 2019 | 37 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2007 | 204 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2010 | 266 | 0.070 |
Why?
|
| Wnt Proteins | 2 | 2006 | 98 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2007 | 881 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 3 | 2018 | 453 | 0.070 |
Why?
|
| Smoking | 2 | 2023 | 865 | 0.070 |
Why?
|
| Quinazolines | 1 | 2007 | 22 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2006 | 108 | 0.070 |
Why?
|
| DNA Mutational Analysis | 2 | 2007 | 195 | 0.070 |
Why?
|
| ErbB Receptors | 1 | 2007 | 114 | 0.070 |
Why?
|
| Exons | 2 | 2007 | 199 | 0.060 |
Why?
|
| Probability | 2 | 2023 | 170 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2007 | 319 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2007 | 220 | 0.060 |
Why?
|
| Transcription, Genetic | 2 | 2007 | 878 | 0.060 |
Why?
|
| Cell Division | 1 | 2007 | 449 | 0.060 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2005 | 16 | 0.060 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2005 | 19 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2006 | 937 | 0.060 |
Why?
|
| Butyrates | 1 | 2005 | 16 | 0.060 |
Why?
|
| Hydroxamic Acids | 1 | 2005 | 27 | 0.060 |
Why?
|
| Neovascularization, Physiologic | 1 | 2005 | 104 | 0.060 |
Why?
|
| beta Catenin | 2 | 2005 | 96 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2005 | 137 | 0.060 |
Why?
|
| Chromones | 1 | 2004 | 19 | 0.060 |
Why?
|
| Proteoglycans | 1 | 2004 | 32 | 0.060 |
Why?
|
| Clone Cells | 1 | 2004 | 114 | 0.050 |
Why?
|
| Laminin | 1 | 2004 | 78 | 0.050 |
Why?
|
| Growth Substances | 1 | 2004 | 34 | 0.050 |
Why?
|
| Imidazoles | 1 | 2004 | 81 | 0.050 |
Why?
|
| Serine | 1 | 2004 | 91 | 0.050 |
Why?
|
| Morpholines | 1 | 2004 | 89 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2004 | 165 | 0.050 |
Why?
|
| Flavonoids | 1 | 2004 | 75 | 0.050 |
Why?
|
| Phenotype | 3 | 2018 | 1199 | 0.050 |
Why?
|
| Biomarkers | 2 | 2019 | 1397 | 0.050 |
Why?
|
| Collagen | 1 | 2004 | 123 | 0.050 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2003 | 5 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2004 | 171 | 0.050 |
Why?
|
| Pyridines | 1 | 2004 | 111 | 0.050 |
Why?
|
| Enzyme Activation | 1 | 2004 | 380 | 0.050 |
Why?
|
| RNA | 2 | 2023 | 423 | 0.050 |
Why?
|
| Cytodiagnosis | 1 | 2003 | 46 | 0.050 |
Why?
|
| Schwann Cells | 1 | 2003 | 8 | 0.050 |
Why?
|
| Polyglycolic Acid | 1 | 2003 | 18 | 0.050 |
Why?
|
| Sciatic Nerve | 1 | 2003 | 26 | 0.050 |
Why?
|
| Peripheral Nerves | 1 | 2003 | 34 | 0.050 |
Why?
|
| Nerve Regeneration | 1 | 2003 | 36 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2003 | 76 | 0.050 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2022 | 45 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2010 | 1513 | 0.050 |
Why?
|
| Bronchi | 1 | 2022 | 78 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2020 | 5654 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2021 | 129 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2019 | 3283 | 0.050 |
Why?
|
| Radiation Dosage | 1 | 2022 | 132 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2021 | 68 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 315 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 172 | 0.040 |
Why?
|
| Body Composition | 1 | 2020 | 152 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2019 | 71 | 0.040 |
Why?
|
| Polymers | 1 | 2003 | 323 | 0.040 |
Why?
|
| Mitosis | 1 | 2021 | 215 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 392 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 38 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2005 | 789 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2005 | 619 | 0.040 |
Why?
|
| Reoperation | 1 | 2019 | 289 | 0.040 |
Why?
|
| Weight Loss | 1 | 2020 | 272 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 640 | 0.030 |
Why?
|
| United States | 2 | 2021 | 7825 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2021 | 868 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1122 | 0.030 |
Why?
|
| NIH 3T3 Cells | 2 | 2007 | 99 | 0.030 |
Why?
|
| Machine Learning | 1 | 2018 | 177 | 0.030 |
Why?
|
| Mass Screening | 1 | 2022 | 690 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1005 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2019 | 319 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2022 | 1989 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2020 | 864 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1558 | 0.030 |
Why?
|
| Rats | 3 | 2005 | 1977 | 0.030 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 53 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 1650 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 190 | 0.030 |
Why?
|
| gamma Catenin | 2 | 2005 | 6 | 0.030 |
Why?
|
| Desmoplakins | 2 | 2005 | 10 | 0.030 |
Why?
|
| Plasmids | 2 | 2006 | 291 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1145 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 860 | 0.030 |
Why?
|
| Massachusetts | 1 | 2020 | 2076 | 0.030 |
Why?
|
| DNA, Complementary | 2 | 2005 | 165 | 0.030 |
Why?
|
| Genes, APC | 1 | 2014 | 10 | 0.030 |
Why?
|
| Unnecessary Procedures | 1 | 2014 | 49 | 0.030 |
Why?
|
| Epigenomics | 1 | 2014 | 62 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 2179 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 517 | 0.020 |
Why?
|
| Child | 1 | 2022 | 4525 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2014 | 292 | 0.020 |
Why?
|
| Adolescent | 1 | 2022 | 6241 | 0.020 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2010 | 8 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 26 | 0.020 |
Why?
|
| Models, Biological | 2 | 2006 | 1177 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2009 | 207 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2007 | 17 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2007 | 19 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 664 | 0.020 |
Why?
|
| Cystectomy | 1 | 2007 | 35 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2007 | 86 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 200 | 0.020 |
Why?
|
| Dactinomycin | 1 | 2006 | 10 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2007 | 519 | 0.020 |
Why?
|
| Lethal Dose 50 | 1 | 2005 | 16 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2006 | 255 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 372 | 0.010 |
Why?
|
| G1 Phase | 1 | 2004 | 56 | 0.010 |
Why?
|
| Tissue Survival | 1 | 2004 | 5 | 0.010 |
Why?
|
| Injections, Intradermal | 1 | 2004 | 8 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2005 | 488 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2004 | 149 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 373 | 0.010 |
Why?
|
| Cell Survival | 1 | 2005 | 569 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2004 | 363 | 0.010 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2004 | 35 | 0.010 |
Why?
|
| Liposomes | 1 | 2004 | 103 | 0.010 |
Why?
|
| Models, Animal | 1 | 2004 | 236 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 335 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 2036 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 2003 | 150 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2004 | 321 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 1592 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 1990 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 1537 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 663 | 0.010 |
Why?
|
| Time Factors | 1 | 2006 | 3761 | 0.010 |
Why?
|
| Risk Factors | 1 | 2007 | 5343 | 0.010 |
Why?
|